Stock Analysis on Net
Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying users area

Try for free

Abbott Laboratories pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Abbott Laboratories, consolidated cash flow statement

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net earnings
Depreciation
Amortization of intangible assets
Share-based compensation
Investing and financing losses, net
Loss on extinguishment of debt
Trade receivables
Inventories
Prepaid expenses and other assets
Trade accounts payable and other liabilities
Income taxes
(Increase) decrease in operating capital
Adjustments to reconcile earnings to net cash from operating activities
Net cash from operating activities
Acquisitions of property and equipment
Acquisitions of businesses and technologies, net of cash acquired
Proceeds from business dispositions
Purchases of investment securities
Proceeds from sales of investment securities
Other
Net cash used in investing activities
Proceeds from issuance (repayments) of short-term debt, net and other
Proceeds from issuance of long-term debt and debt with maturities over 3 months
Repayments of long-term debt and debt with maturities over 3 months
Purchases of common shares
Proceeds from stock options exercised
Dividends paid
Other
Net cash used in financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Cash flow statement item Description The company
Net cash from operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Abbott Laboratories net cash from operating activities decreased from 2021 to 2022 and from 2022 to 2023.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Abbott Laboratories net cash used in investing activities increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.
Net cash used in financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Abbott Laboratories net cash used in financing activities decreased from 2021 to 2022 but then slightly increased from 2022 to 2023.